摘要: Abstract Concerns about the safety and adequacy of blood supply have fostered twenty years research into so-called “blood substitutes” among them oxygen carriers based on modified hemoglobin. Although none these materials has yet been licensed for use in North America or Europe, results clinical trials increased our understanding delivery its regulation. In particular, examination basis vasoactivity observed with some hemoglobin led to insight that several colligative properties solutions, such as their diffusion coefficient oxygen, viscosity colloid oncotic pressure, are important determinants efficacy.